In line with our findings, miR-15b has been shown to inhibit angiogenesis in proliferative diabetic retinopathy via targeting VEGFA, inhibit vascular smooth muscle cells in peripheral artery disease via targeting IGF1R, counteract senescence-associated mitochondrial dysfunction in skin aging via targeting SIRT4, and suppress Th17 Differentiation in multiple sclerosis by targeting O-GlcNAc [42,43,44,45]. The gene discussed is VEGFA; the disease is peripheral arterial disease.